The clinical-stage biotechnology company is developing human vaccines against infectious diseases using its Modified Vaccinia Ankara - Virus-Like Particle (MVA-VLP) vaccine platform.
GeoVax Labs developing a therapy that potentially cures Hepatitis B
Quick facts: GeoVax Labs
Market Cap: $106.84 k
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE